Company Profile: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (Stock Code: 1349)
Background
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is a Chinese biopharmaceutical company specializing in the research, development, manufacturing, and sale of bio-pharmaceutical products. Established in 1996, the company is headquartered in Shanghai, China. Its mission is to advance healthcare through innovative therapies, and its vision is to become a leading global biopharmaceutical enterprise. Operating within the healthcare sector, the company holds significant importance in the pharmaceutical industry, particularly in the development of targeted therapies for various cancers.
Key Strategic Focus
The company's strategic focus centers on the development of novel biopharmaceutical products, with an emphasis on:
- Core Objectives: Advancing innovative therapies, expanding its product portfolio, and enhancing global market presence.
- Areas of Specialization: Oncology, particularly targeted therapies for various cancers.
- Key Technologies Utilized: Genetic engineering platforms, photodynamic therapy, and osmotic pump technology.
- Primary Markets Targeted: Domestic Chinese market and international markets, focusing on regions with high unmet medical needs in oncology.
Financials and Funding
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is a publicly traded company listed on the Hong Kong Stock Exchange under the stock code 1349. As of the latest available data, the company has a market capitalization of approximately HKD 3.33 per share. The company has demonstrated financial stability with a debt-free balance sheet, indicating a strong financial position. Specific details regarding recent funding rounds and the utilization of capital are not publicly disclosed.
Pipeline Development
The company's pipeline includes several key candidates at various stages of development:
- Trop2-SN38 ADC: In Phase III clinical trials for triple-negative breast cancer.
- CD30-DM1 ADC: Completed Phase I clinical trials for tumors.
- Trop2-BB05 ADC: In Phase I clinical trials for tumors.
- DLL3-BB05 ADC: In Phase I clinical trials for tumors.
- HER2 ADC: In Phase I clinical studies for tumors.
- Hemoporfin: Completed Phase IV clinical trials for port wine stain.
- Aminolevulinic Acid-Based Therapies: Various formulations in Phase II and IV clinical trials for conditions such as cervical diseases infected by HPV, actinic keratosis, acne, gliomas, bladder cancer, and breast cancer.
- Controlled-Release Carbidopa/Levodopa Tablets: Completed Phase II clinical trials for early Parkinson’s disease.
- Obeticholic Acid: For the treatment of hepatobiliary/autoimmune diseases.
Technological Platform and Innovation
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. distinguishes itself through several proprietary technologies and scientific methodologies:
- Proprietary Technologies: Genetic engineering platforms for antibody-drug conjugates (ADCs), photodynamic therapy platforms, and osmotic pump technology for controlled drug release.
- Significant Scientific Methods: Advanced assays for drug efficacy and safety, machine learning algorithms for drug discovery, and innovative delivery systems for targeted therapies.
Leadership Team
The leadership team comprises experienced professionals:
- Da Jun Zhao: Co-Founder, General Manager, and Executive Chairman since 2002.
- Xue Yan: Chief Financial Officer, Deputy General Manager, Company Secretary, and Executive Director since 2010.
- Yu Kuan Tang: Chairman of the Supervisory Committee since 2020.
- Xiao Yang Yu: Non-Executive Director since 2013.
- Bo Shen: Non-Executive Director since 2012.
- Hong Guang Wang: Independent Non-Executive Director since 2023.
- Siu Wing Lam: Independent Non-Executive Director since 2023.
- Pei Long Xu: Independent Non-Executive Director since 2023.
- Ai Guo Zhou: Supervisor since 2023.
- Jian Huang: Independent Chairman of Supervisory Board since 2017.
- Ya Nan Qu: Employee Representative Supervisor since 2023.
Market Insights and Competitor Analysis
The biopharmaceutical industry is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The market is expanding due to increasing global healthcare needs and advancements in biotechnology. Key competitors include multinational pharmaceutical companies and domestic Chinese biopharmaceutical firms. These competitors focus on similar therapeutic areas, such as oncology, and employ advanced technologies in drug development.
Strategic Collaborations and Partnerships
The company engages in various collaborations and partnerships to enhance its research capabilities, expand its product portfolio, and enter new markets. Specific details of these collaborations are not publicly disclosed.
Operational Insights
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. maintains a competitive edge through its innovative product pipeline, strong financial position, and experienced leadership team. Its focus on targeted therapies and advanced drug delivery systems positions it favorably in the biopharmaceutical market.
Strategic Opportunities and Future Directions
The company aims to expand its global presence by entering new markets, particularly in regions with high unmet medical needs. It plans to leverage its technological platforms to develop novel therapies and strengthen its position in the oncology segment. Ongoing research and development efforts are focused on advancing its pipeline and achieving regulatory approvals for its products.
Social Media Profiles
- LinkedIn: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- WeChat: Fudan Zhangjiang Bio-Pharmaceutical
